alnuctamab: improved route of administration and optimized dose level & dosing schedule
Published 1 year ago • 163 plays • Length 2:05Download video MP4
Download video MP3
Similar videos
-
2:11
synergistic activity of alnuctamab and celmods in multiple myeloma preclinical models
-
2:02
alnuctamab, a bcma x cd3 tce, in the treatment of multiple myeloma
-
2:50
phase i study of abbv383, a novel bcmaxcd3 bispecific antibody, in r/r multiple myeloma
-
1:55
benefits of alnuctamab in the treatment of r/r multiple myeloma
-
2:44
dual-targeting bispecific antibody alnuctamab in r/r multiple myeloma
-
4:57
ash 2022: talquetamab showing promise in multiple myeloma clinical trial
-
25:56
lecture: cusp overlap and commissural alignment in tavr
-
2:50
ibm maas360: updating cloud extender manually
-
2:46
subcutaneous alnuctamab in patients with r/r multiple myeloma: the results of a phase i trial
-
2:38
the value of subcutaneous alnuctamab for the treatment of r/r multiple myeloma
-
1:14
phase i study of abbv-383, a bcma×cd3 bispecific antibody, in r/r myeloma
-
1:33
sequencing and the management of adverse events when administering bispecifics for myeloma
-
1:30
evaluating the optimal duration of cpx-351 treatment & best timing for allosct consolidation in aml
-
0:47
overview of the phase iii enhance trial schema
-
1:54
fusion-aml-001: molecular changes associated with azacitidine & durvalumab in tp53m aml and hr-mds
-
1:04
emn 27: phase ii study of belantamab mafodotin in patients with r/r al amyloidosis
-
2:02
phase ib/iia study of azd4573 and acalabrutinib in patients with r/r dlbcl
-
1:43
extended follow-up of the alpine trial: superior outcomes with zanubrutinib in r/r cll/sll
-
2:43
the management of advanced phase mpns
-
2:25
advancements and challenges in bispecific antibodies for the treatment of b-nhl
-
2:01
elm-2 trial: using ctdna and mrd to measure odronextamab outcomes in dlbcl and fl